Integrated BioSci Investing: Latest Bioscience Breakthroughs

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.

Integrated BioSci Investing: CAR-T FDA Approved And Promising Developments

Summary

• CAR-TCR received FDA approval for the treatment of non-Hodgkin lymphoma.
• Kite, Exelixis, and Spectrum are delivering stellar returns for subscribers.
• We intend to increase the forecasting of both clinical and regulatory catalysts.
• Integrated BioSci Investing portfolio is yielding an overall robust return.

The biotech sector is highly promising with merger and acquisition to boost for stellar profits. In the past 52-weeks, Kite Pharma (NASDAQ:KITE) was acquired by Gilead Sciences Inc (NASDAQ:GILD) for $11.9B (on Aug. 28, 2017). This catapulted our portfolio’s profits on Kite to 82%. As this story is playing out, the FDA approved CAR-TCR as the treatment for non-Hodgkin lymphoma (on Oct. 18, 2017). The stellar news (for both patients and investors) gives further credence to our thesis on CAR-TCR (as a major breakthrough since the introduction of chemotherapy, half a decade prior).

Source: Google Finance

Stellar BioSciences For Value Investors

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.

A Look At The Twin Towers Of Cancer Therapeutics

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.

MannKind Corporation: Can Afrezza Improved Labeling Fuel A Successful Comeback?

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.

Alarmed PBC Data Yet The NASH Franchise Is Strong For Intercept

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.

What’s Next For Spectrum Investors After The Recent Poziotinib Win?

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.